"Benzimidazoles" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
Compounds with a BENZENE fused to IMIDAZOLES.
| Descriptor ID |
D001562
|
| MeSH Number(s) |
D03.633.100.103
|
| Concept/Terms |
|
Below are MeSH descriptors whose meaning is more general than "Benzimidazoles".
Below are MeSH descriptors whose meaning is more specific than "Benzimidazoles".
This graph shows the total number of publications written about "Benzimidazoles" by people in this website by year, and whether "Benzimidazoles" was a major or minor topic of these publications.
To see the data from this visualization as text,
click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1996 | 0 | 1 | 1 |
| 1997 | 0 | 2 | 2 |
| 1999 | 0 | 1 | 1 |
| 2000 | 0 | 1 | 1 |
| 2001 | 1 | 1 | 2 |
| 2002 | 0 | 1 | 1 |
| 2003 | 3 | 3 | 6 |
| 2004 | 2 | 3 | 5 |
| 2005 | 1 | 4 | 5 |
| 2006 | 3 | 0 | 3 |
| 2007 | 1 | 1 | 2 |
| 2008 | 2 | 1 | 3 |
| 2009 | 2 | 0 | 2 |
| 2010 | 0 | 1 | 1 |
| 2011 | 5 | 3 | 8 |
| 2012 | 3 | 2 | 5 |
| 2013 | 3 | 1 | 4 |
| 2014 | 2 | 3 | 5 |
| 2015 | 3 | 2 | 5 |
| 2016 | 6 | 2 | 8 |
| 2017 | 4 | 3 | 7 |
| 2018 | 2 | 1 | 3 |
| 2019 | 3 | 1 | 4 |
| 2020 | 3 | 3 | 6 |
| 2021 | 1 | 1 | 2 |
| 2022 | 1 | 1 | 2 |
| 2023 | 0 | 8 | 8 |
| 2024 | 1 | 3 | 4 |
| 2025 | 1 | 2 | 3 |
| 2026 | 3 | 3 | 6 |
To return to the timeline,
click here.
Below are the most recent publications written about "Benzimidazoles" by people in Profiles.
-
CDK4/6 inhibitors plus endocrine therapy versus endocrine monotherapy in hormone receptor-positive, HER2-negative advanced breast cancer: a reconstructed individual patient data meta-analysis of phase 3 randomised controlled trials. Lancet Oncol. 2026 May; 27(5):592-603.
-
Defective DNA Damage Response Is a Targetable Therapeutic Vulnerability in ESR1-Mutant Breast Cancer. Cancer Res. 2026 Apr 02; 86(7):1707-1723.
-
A ?-opioid receptor superagonist analgesic with minimal adverse effects. Nature. 2026 Apr; 652(8112):1393-1404.
-
Candesartan cilexetil disrupts methicillin-resistant Staphylococcus aureus membrane and potentiates gentamicin and polymyxin B activity. Nat Commun. 2026 Mar 15; 17(1).
-
Obicetrapib in patients with heterozygous familial hypercholesterolemia: the BROOKLYN randomized clinical trial. Nat Med. 2026 Mar; 32(3):1052-1060.
-
The 201 Trial: a placebo-controlled randomized phase 2 study of safety and tolerance of the c-Abl kinase inhibitor risvodetinib in untreated Parkinson's disease. Nat Aging. 2026 Mar; 6(3):626-635.
-
Design, synthesis, and biological evaluation of Benzimidazole-Aminopyrimidine hybrids as selective P38a MAPK inhibitors targeting Neuroinflammation in an AlCl3-induced rat model of Alzheimer's disease. Bioorg Chem. 2026 02; 169:109391.
-
Phase 2 trial of veliparib, local irradiation, and temozolomide in patients with newly diagnosed high-grade glioma: a Children's Oncology Group study. Neuro Oncol. 2025 May 15; 27(4):1092-1101.
-
Non-adherence of cyclin-dependent kinases 4 and 6 inhibitors reduces overall and progression-free survival in patients with hormone receptor-positive breast cancer. Breast Cancer Res Treat. 2025 Jul; 212(1):71-78.
-
A Randomized, Double-Blind, Phase 3 Safety and Efficacy Study of Ridinilazole Versus Vancomycin for Treatment of Clostridioides difficile Infection: Clinical Outcomes With Microbiome and Metabolome Correlates of Response. Clin Infect Dis. 2024 06 14; 78(6):1462-1472.